Interest of the SPECT-CT Scan SUVspect in the New Generation of Gamma-cameras With Semiconductor


Since 2017, a revolution began in the departments of nuclear medicine, with the routine use of gamma-cameras with semiconductor. These gamma-cameras (which obtained the CE-marking in 2016), offer a technological breakthrough by providing an additional information. They allow "to quantify" for the 1st time in clinical routine conditions, the quantity of radioactivity, by means of a "SUVspect", in a volume of interest, while respecting the recommendations of best practice of the learned societies of French nuclear medicine (SFMN), European (EANM) and American (SNM), without injection of tracer nor acquisition or additional irradiation. The SUVspect is therefore an indicator of the quantity of tracer in a given volume of acquisition.

Until now, the interpretation criteria of scintigraphies are based on the homogeneity of distribution of a tracer in the explored organ (for single organs such as the heart or the thyroid, for example) or in the asymmetry of distribution of the tracer (for the double organs, such as the kidney or the joints).

This new gamma-camera allows to study the distribution of the radio-tracers in "list" mode, allowing to retrospectively reconstruct the images in various ways (for example, by modifying the size of the matrix of acquisition, the energy windows, the time of acquisition). Therefore, we can simulate and propose modifications in current procedures.

Every patient referred to our department of nuclear medicine to undergo a scintigraphy with a tracer of nuclear medicine (with a marketing authorization) can, while benefiting from an examination by this gamma-camera, to be the object of this study, and to profit from this additional information.

So, without changing the diagnosis or the usual care, we wish to take advantage of this additional information to improve the criteria of interpretation of our examinations.

This possibility being new, there is no available bibliography (our department is the 5th department of nuclear medicine in Europe to equip itself with this large field-of-view gamma-camera CZT, the DNM 670, made by General Electric), while 2961 articles speak about the SUVmax (in PET) in Pubmed.

Full Title of Study: “Quantification in Nuclear Medicine: Interest of the in SPECT-CT Scan SUVspect in Thea New Generation of Gamma-cameras With Semiconductor. Data Collection for the Constitution of an Observatory of Scintigraphies”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 30, 2023


  • Diagnostic Test: SPECT-CT Scan
    • Injection of a Tracer and SPECT-CT Scan

Arms, Groups and Cohorts

  • Thyroid Diseases
    • SPECT-CT Scan
  • Heart Diseases
    • SPECT-CT Scan
  • Bone Diseases
    • SPECT-CT Scan
  • Brain Diseases
    • SPECT-CT Scan
  • Kidney Diseases
    • SPECT-CT Scan

Clinical Trial Outcome Measures

Primary Measures

  • SUVspect
    • Time Frame: 5 years
    • Pathological threshold (SUVspect) for every type of scintigraphy

Secondary Measures

  • Matrix size
    • Time Frame: 5 years
    • Optimize the reconstruction parameters of the images
  • duration of image acquisition
    • Time Frame: 5 years
    • Optimize the reconstruction parameters of the images

Participating in This Clinical Trial

Inclusion Criteria

  • informed adult patients referred to our department of nuclear medicine for a nuclear medicine exploration

Exclusion Criteria

  • Refusal to participate
  • Patient under guardianship

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Lille Catholic University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Tanguy Blaire, MD, Principal Investigator, GIE HUMANITEP, GHICL
    • Alban Baillez, MD, Principal Investigator, GIE HUMANITEP, GHICL
  • Overall Contact(s)
    • Amélie Lansiaux, MD, PhD, 03 20 22 52 69,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.